Literature DB >> 18833271

Challenges in the development of an HIV-1 vaccine.

Dan H Barouch1.   

Abstract

The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically important global health priority. Despite recent advances in our understanding of HIV-1 pathogenesis and immunology, however, major scientific obstacles remain. Prototype HIV-1 vaccine candidates aimed at eliciting humoral and cellular immune responses have so far failed to protect against HIV-1 infection or to reduce viral loads after infection in clinical efficacy studies. A renewed and coordinated commitment to basic discovery research, preclinical studies and clinical trials will therefore be required to overcome the hurdles currently facing the field. Here I review key challenges and future prospects in the quest to develop a prophylactic HIV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18833271      PMCID: PMC2572109          DOI: 10.1038/nature07352

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  90 in total

1.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.

Authors:  Qingsheng Li; Lijie Duan; Jacob D Estes; Zhong-Min Ma; Tracy Rourke; Yichuan Wang; Cavan Reilly; John Carlis; Christopher J Miller; Ashley T Haase
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

2.  Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Authors:  Danilo R Casimiro; Fubao Wang; William A Schleif; Xiaoping Liang; Zhi-Qiang Zhang; Timothy W Tobery; Mary-Ellen Davies; Adrian B McDermott; David H O'Connor; Arthur Fridman; Ansu Bagchi; Lynda G Tussey; Andrew J Bett; Adam C Finnefrock; Tong-ming Fu; Aimin Tang; Keith A Wilson; Minchun Chen; Helen C Perry; Gwendolyn J Heidecker; Daniel C Freed; Anthony Carella; Kara S Punt; Kara J Sykes; Lingyi Huang; Virginia I Ausensi; Margaret Bachinsky; Usha Sadasivan-Nair; David I Watkins; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Authors:  Photini Kiepiela; Alasdair J Leslie; Isobella Honeyborne; Danni Ramduth; Christina Thobakgale; Senica Chetty; Prinisha Rathnavalu; Corey Moore; Katja J Pfafferott; Louise Hilton; Peter Zimbwa; Sarah Moore; Todd Allen; Christian Brander; Marylyn M Addo; Marcus Altfeld; Ian James; Simon Mallal; Michael Bunce; Linda D Barber; James Szinger; Cheryl Day; Paul Klenerman; James Mullins; Bette Korber; Hoosen M Coovadia; Bruce D Walker; Philip J R Goulder
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

4.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.

Authors:  Joseph J Mattapallil; Daniel C Douek; Brenna Hill; Yoshiaki Nishimura; Malcolm Martin; Mario Roederer
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

5.  HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.

Authors:  Ulrike Wille-Reece; Barbara J Flynn; Karin Loré; Richard A Koup; Ross M Kedl; Joseph J Mattapallil; Walter R Weiss; Mario Roederer; Robert A Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-11       Impact factor: 11.205

6.  Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.

Authors:  J C Learmont; A F Geczy; J Mills; L J Ashton; C H Raynes-Greenow; R J Garsia; W B Dyer; L McIntyre; R B Oelrichs; D I Rhodes; N J Deacon; J S Sullivan
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

7.  Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors:  Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

8.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

9.  Structure of an unliganded simian immunodeficiency virus gp120 core.

Authors:  Bing Chen; Erik M Vogan; Haiyun Gong; John J Skehel; Don C Wiley; Stephen C Harrison
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

10.  Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

Authors:  X Jin; D E Bauer; S E Tuttleton; S Lewin; A Gettie; J Blanchard; C E Irwin; J T Safrit; J Mittler; L Weinberger; L G Kostrikis; L Zhang; A S Perelson; D D Ho
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

View more
  150 in total

1.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

3.  Constraints on HIV-1 diversity from protein structure.

Authors:  Jeongmin Woo; David L Robertson; Simon C Lovell
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

4.  A general protease digestion procedure for optimal protein sequence coverage and post-translational modifications analysis of recombinant glycoproteins: application to the characterization of human lysyl oxidase-like 2 glycosylation.

Authors:  Kathryn R Rebecchi; Eden P Go; Li Xu; Carrie L Woodin; Minae Mure; Heather Desaire
Journal:  Anal Chem       Date:  2011-10-27       Impact factor: 6.986

5.  "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.

Authors:  P A Newman; S Yim; A Daley; R Walisser; R Halpenny; W Cunningham; M Loutfy
Journal:  Vaccine       Date:  2010-11-12       Impact factor: 3.641

6.  Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer.

Authors:  Denong Wang; Laila Dafik; Rosalie Nolley; Wei Huang; Russell D Wolfinger; Lai-Xi Wang; Donna M Peehl
Journal:  Drug Dev Res       Date:  2013-03       Impact factor: 4.360

7.  Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.

Authors:  Maolin Lu; Xiaochu Ma; Nick Reichard; Daniel S Terry; James Arthos; Amos B Smith; Joseph G Sodroski; Scott C Blanchard; Walther Mothes
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

8.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

9.  Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.

Authors:  Marlyse C Knuchel; René R Marty; Teldja Neige Azzouz Morin; Orhan Ilter; Armando Zuniga; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

10.  Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Ann Cheung; James R Perry; Darrick Carter; Steve Reed; Hanneke Schuitemaker; Maria Grazia Pau; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  Vaccine       Date:  2014-02-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.